Glucose-lowering drugs include sulfonylureas, biguanides, insulin sensitizers, α-glucosidase inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, etc. The newer and safer drugs are GLP-1 receptor agonists, such as dulaglucagon and somatostatin. GLP-1 agonists can enhance insulin secretion, inhibit glucagon secretion, and can delay gastric emptying, appetite suppression, so as to achieve the effect of lowering blood glucose. GLP-1 agonists alone have a small risk of hypoglycemia, and also have the effect of weight loss, lowering blood pressure, improve lipid profile, etc.. Newer drugs include dulaglutide and somatostatin. GLP-1 receptor agonists have a relatively high safety profile, with nausea, abdominal pain, diarrhea and other discomforts associated with their use. The drug is contraindicated in patients with allergies to the ingredients and in patients with a history of medullary thyroid cancer or a family history of the disease. Patients with diabetes should use the drug under medical supervision.